BIORHYTHMS AND CHRONOTHERAPY IN CARDIOVASCULAR-DISEASE

被引:27
作者
COOKE, HM
LYNCH, A
机构
[1] MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA
[2] HARVARD UNIV, SCH MED, HARVARD MED NEWS, BOSTON, MA USA
来源
AMERICAN JOURNAL OF HOSPITAL PHARMACY | 1994年 / 51卷 / 20期
关键词
CARDIOVASCULAR DISEASES; CHRONOPHARMACOLOGY; CIRCADIAN RHYTHM; DOSAGE SCHEDULES;
D O I
10.1093/ajhp/51.20.2569
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recent findings about the effects of biorhythms on cardiovascular disorders are reviewed, and their implications for drug therapy are discussed. The chronobiological approach to physiology evaluates time-dependent changes in biological functions and considers those changes to be multifactorial. Characterization of disease states with this approach allows more accurate determination of the times when patients are at highest risk and therefore in greatest need of preventive measures; it also provides a mechanism for designing optimal drug regimens. There is evidence of circadian variations in the occurrence of myocardial ischemia, acute myocardial infarction, ventricular tachycardia, and sudden cardiac death. Many cardiovascular disorders occur with greatest frequency between 0600 and 1200 in the general population. Blood pressure, too, follows a distinct circadian pattern. Factors affecting circadian variations in cardiovascular disorders include physiological determinants, such as heart rate,catecholamine release, and platelet aggregation-which themselves vary cyclically-and exogenous factors, such as mental stress, anxiety, and physical activity. In chronotherapy, circadian variations in disease states and in the pharmacodynamic properties of drugs are exploited to improve prevention and treatment. Conditions in which research suggests a chronotherapeutic approach may be advantageous include thromboembolism, hypertension, stable exertional angina, variant angina, sustained ventricular tachycardia, and acute myocardial infarction. Information on circadian patterns in the occurrence of many cardiovascular disorders is enabling clinicians to tailor treatment in ways that may lead to improved patient outcomes.
引用
收藏
页码:2569 / 2580
页数:12
相关论文
共 121 条
  • [51] DOUBLE-PEAKING CIRCADIAN VARIATION IN THE OCCURRENCE OF SUSTAINED SUPRAVENTRICULAR TACHYARRHYTHMIAS
    KUPARI, M
    KOSKINEN, P
    LEINONEN, H
    [J]. AMERICAN HEART JOURNAL, 1990, 120 (06) : 1364 - 1369
  • [52] LISINOPRIL - A PRELIMINARY REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE IN HYPERTENSION AND CONGESTIVE HEART-FAILURE
    LANCASTER, SG
    TODD, PA
    [J]. DRUGS, 1988, 35 (06) : 646 - 669
  • [53] LAZARUS JH, 1988, J HUM HYPERTENS, V2, P191
  • [54] LEMMER B, 1989, Z KARDIOL, V78, P61
  • [55] CHRONOPHARMACOKINETICS AND CHRONOPHARMACODYNAMICS OF CARDIOVASCULAR ACTIVE-DRUGS - PROPRANOLOL, ORGANIC NITRATES, NIFEDIPINE
    LEMMER, B
    SCHEIDEL, B
    BEHNE, S
    [J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES-SERIES, 1991, 618 : 166 - 181
  • [56] CHRONOPHARMACOKINETICS AND CARDIOVASCULAR EFFECTS OF NIFEDIPINE
    LEMMER, B
    NOLD, G
    BEHNE, S
    KAISER, R
    [J]. CHRONOBIOLOGY INTERNATIONAL, 1991, 8 (06) : 485 - 494
  • [57] CLINICAL CHRONOPHARMACOLOGY OF ORAL SUSTAINED-RELEASE ISOSORBIDE-5-MONONITRATE IN HEALTHY-SUBJECTS
    LEMMER, B
    SCHEIDEL, B
    BLUME, H
    BECKER, HJ
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (01) : 71 - 75
  • [58] LEVI F, 1981, NEOPLASMS COMP PATHO, P267
  • [59] CIRCADIAN VARIATION OF VENTRICULAR-TACHYCARDIA IN ACUTE MYOCARDIAL-INFARCTION
    LUCENTE, M
    REBUZZI, AG
    LANZA, GA
    TAMBURI, S
    CORTELLESSA, MC
    COPPOLA, E
    IANNARELLI, M
    MANZOLI, U
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1988, 62 (10) : 670 - 674
  • [60] BLOOD-PRESSURE RESPONSE TO LABETALOL IN TWICE AND 3 TIMES DAILY ADMINISTRATION DURING A 24-HOUR PERIOD
    MANCIA, G
    POMIDOSSI, G
    PARATI, G
    BERTINIERI, G
    GRASSI, G
    NAVONE, F
    FERRARI, A
    GREGORINI, L
    ZANCHETTI, A
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 13 : S27 - S35